Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Head and neck cancer : Key messages from ASCO 2011 Targeted therapy : Ang KK et al.J Clin Oncol 29: 2011 (suppl; abstr 5500) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10 2&abstractID=79086 Conclusion : The addition of cetuximab (CET) to concurrent accelerated radiation plus cisplatin failed to improve progression-free survival and overall survival in stage III-IV head and neck squamous cell carcinomas (HNC) Comment : The results of this study, with the failure of cetuximab addition to improve outcome, were surprising. They show that "more" is not necessarily more active even when the trial has an excellent rationale. This reminds us also about the necessity of getting evidence-based data before introducing a new drug or a new combination into clinical practice. The RTOG launched a phase III trial in patients with stage III-IV carcinoma of the oropharynx, larynx, and hypopharynx and good performance status. The experimental regimen (Arm A) consisted of a loading dose and 6-7 weekly doses of CET given in conjunction with the control arm (B) of 70-72 Gy (6 weeks) + 2 cycles of CDDP (q3 weeks). From 11/’05 to 3/’09, 447 evaluable patients were randomized to Arm A and 448 to Arm B. The median follow-up was 2.4 years for surviving patients There were no significant differences in progression-free survival (HR [A/B]: 1.05, 0.84-1.29; P=0.66, the primary endpoint, or in overall survival (HR: 0.87, 0.66-1.15; P=0.17). Prevention of toxicity : Anthunes HS et al. J Clin Oncol 29: 2011 (suppl; abstr LBA5524) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=10 2&abstractID=83204 Conclusion : Upfront low-level laser therapy (LLLT) in patients submitted to concurrent chemoradiation (CRT) is an effective tool in reducing grades 3/4 oral mucositis (OM), oral pain, use of narcotic and gastrostomia and improves quality of life. Comment : This study confirms the effectiveness of a technique experimented since several years at Institut Bordet. We believe that such preventive treatment should be put in place at a large scale as avoiding to patients with head and neck cancer treated by chemoradiation a highly painful side effects. Oral mucositis (OM) remains a limiting factor in in head and neck squamous cell carcinomas (HNSCC) patients (pts) treated with chemoradiation (CRT). From Jun 2007 to Dec 2010, 47 LLLT and 47 placebo pts were randomized between LLLT used daily (660nm-100mW4J/cm²) and placebo. CRT consisted of conventional RT 70.2 Gy (1.8Gy/d, 5 times/wk) + concurrent cisplatin 100 mg/m2 every 3 wks. In the LLLT arm the incidence of OM G 3/4 was only 6.4% versus 48% in the placebo arm; HR of 0.13 (95% CI, p<0.001). LLLT patients had less severe pain (p=0.012), used less narcotic analgesic, HR 0.33 (IC 95%, p<0.001) and required less gastrostomia, HR 0.037 (IC 95%, p= 0.005). No LLLT pts had RT interrupted due to OM. Results of EORTC QLQ-C30 also clearly favored the LLLT arm.